Allergan Buys Global Rights To Serenity's Phase III Drug For Frequent Nighttime Urination
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan also will have right of first refusal for Ser-120 in pediatric bedwetting, though this use is in early stage development.
You may also be interested in...
Allergan Exits Noctiva Partnership With Serenity Just As FDA Approves Controversial Drug
Just as Noctiva obtains FDA approval as the first drug for nocturia due to nocturnal polyuria, Allergan bails on collaboration signed seven years ago.
Allergan Nasal Spray For Frequent Nighttime Urination Faces Review Hurdles
Advisory committee will weigh in on desmopressin as FDA questions broad indication and says clinical meaningfulness of treatment effects for Serenity Pharmaceuticals/Allergan’s product vs. placebo are unclear.
Allergan Seeks To Extend Botox Use To Overactive Bladder
During an R&D day March 28, Allergan highlighted its growth strategy for Botox, which includes expansion into new indications like overactive bladder; the company submitted an sBLA for the indication.